Australia is eagerly awaiting the arrival of retatrutide, a novel dual GIP and GLP-1 receptor agonist that's generating significant buzz in the global weight management landscape. Developed by Novo Nordisk, this https://haseebioco836741.wikihearsay.com/4575727/novo_nordisk_s_retatrutide_australia_a_potential_solution_for_obesity_treatment